PMDA drug package insert

アレモ皮下注15mg

PMDA Prescription drug · ノボ ノルディスク ファーマ株式会社 · package insert May 7, 2025

Key facts

Brand names アレモ皮下注15mg, アレモ皮下注60mg, アレモ皮下注150mg, アレモ皮下注300mg
Nonproprietary names コンシズマブ(遺伝子組換え)
Companies 製造販売元/ノボ ノルディスク ファーマ株式会社
Product type Prescription drug
Therapeutic category 抗TFPIモノクローナル抗体
Therapeutic category codes 876349
YJ codes 6343458G1020, 6343458G2026, 6343458G3022, 63494B0G4025
Approval numbers 30500AMX00276000, 30500AMX00277000, 30500AMX00281000, 30500AMX00278000
Package insert edition 第3版
Package insert date May 7, 2025
PMDA document key 620023_6343458G1020_1
PMDA company code 620023

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • Yes PMDA review report published
  • Yes Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)